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Heterogeneous genetic background of Hungarian patients with
pheochromocytoma/paraganglioma requires gene panel testing
Bala´zs Sarkadi1, Sa´ra Zakaria´s1, Istva´n Liko´2, Vince Korne´l Grolmusz1,2,
Henriett Butz1,2,3, Miklo´s To´th1, Nikolette Szu¨cs1, Pe´ter Igaz4
& Attila Pato´cs2,3,4
12nd Department of Medicine, Semmelweis University, Budapest, Hungary;
2Lendu¨let” Hereditary Endocrine Tumours Research Group, Hungarian
Academy of Sciences – Semmelweis University, Budapest, Hungary;
3Department of Laboratory Medicine, Semmelweis University, Budapest,
Hungary; 4Molecular Medicine Research Group, Hungarian Academy of
Sciences – Semmelweis University, Budapest, Hungary.
Introduction
Pheochromocytomas and paragangliomas (Pheo/PGL) are rare neuroendocrine
tumours arising from the adrenal medulla or the symphathetic paraganglia,
respectively. Germline mutations are present inw40% of the patients. To date, at
least 16 genes have been demonstrated to be involved in the genetic background
of Pheo/PGL. Prioritization in order of genes tested can be applied, but if the
probability of a disease-associated germline mutation exceeds 10% the testing of
all susceptibility genes is recommended. Using next generation sequencing
(NGS) based methods for genetic testing of Pheo/PGL associated genes
progressively becomes part of the routine diagnostics.
Objective
To assess the genetic background of Hungarian patients with Pheo/PGL and to
develop a NGS based gene panel assay for analysis of Pheo/PGL susceptibility
genes.
Methods
We examined 131 patients with the diagnosis of Pheo/PGL diagnosed and nursed
at the 2nd Department of Medicine, Semmelweis University. The prevalence of
the germline mutations of Pheo/PGL genes was determined using conventional
methods. Genotype-phenotype correlations were evaluated. A gene panel
covering 15 genes (RET, VHL, NF1, EPAS, EGLN1, KIF1B, SDHA, SDHB,
SDHAF2, SDHC, SDHD, FH, MAX, TMEM127, MEN1) was developed and
analytical sensitivity was evaluated on 36 patients with known genetic
background. Library preparation was performed using SeqCapEZ capture
platform with our probe design. Illumina MiSeq instrument was used for
sequencing. Sequencing data were analysed with GATK workflow. Variant
annotation was performed with SNPeffect.
Results
Germline mutations of Pheo/PGL genes were present in at 34% of the patients: 10
(7.6%) SDHB, 9 (6.9%) RET, 5 (3.8%) VHL, TMEM127, MDH2, 4 (3%) NF1, 3
(2.3%) SDHD, 2 (1.5%) SDHC and KIF1B. 5 of 10 SDHB mutation carriers
developed malignant disease. Homozygous form of a MDH2 variant was
associated with malignancy. Among the 10 patients with bilateral adrenal Pheo 4
RET, 2 TMEM127 and 1 VHL mutations were identified. The coverage of genes in
our panel was higher than 150 reads in all regions and all known mutations were
correctly identified.
Discussion
Our findings regarding the prevalence of germline mutations in the development
of Pheo/PGL are in accordance with the literature. No founder mutation occurred
in our population as we could detect mutations in 9 genes, underlining the need of
novel methods for mutation analysis in everyday clinical practice. Our NGS-
based gene panel performed accurately, however two recently identified genes
(MDH2, GOT2) were not covered.
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Gastroenteropancreatic neuroendocrine tumors are predictive for a
positive MEN1 germline mutation test: evidence from Hungarian
MEN1 cohort
Annama´ria Ko¨vesdi1,2, Katalin Balogh1, Miklo´s To´th1, Nikolette Szu¨cs1,
Beatrix Sa´rma´n1, Pe´ter Pusztai1, Pe´ter Reismann1, Aniko´ Somogyi1,
Katalin Borka3, Annama´ria Erdei4, Veronika Dea´k5, Zsuzsanna Valkusz6,
Pe´ter Igaz1,7, Attila Pato´cs2,7,8 & Vince Korne´l Grolmusz1,2
12nd Department of Medicine, Semmelweis University, Budapest, Hungary;
2“Lendu¨let” Hereditary Endocrine Tumours Research Group, Hungarian
Academy of Sciences – Semmelweis University, Budapest, Hungary; 32nd
Department of Pathology, Semmelweis University, Budapest, Hungary; 41st
Department of Medicine, University of Debrecen, Debrecen, Hungary;
5Kaposi Mo´r County Hospital, Kaposva´r, Hungary; 61st Department of
Medicine, University of Szeged, Szeged, Hungary; 7Molecular Medicine
Research Group, Hungarian Academy of Sciences – Semmelweis
University, Budapest, Hungary; 8Department of Laboratory Medicine,
Semmelweis University, Budapest, Hungary.
Objective
Multiple endocrine neoplasia type 1 (MEN1) is a rare heritable tumor syndrome
caused by germline mutations of MEN1 gene affecting mainly the parathyroid,
pituitary and pancreas. Phenotype varies widely, even in first-degree relatives.
Recently it has been shown that functionally active gastroenteropancreatic
neuroendocrine tumors (GEP-NETs), initially frequently diagnosed as sporadic
cases, lead to MEN1 diagnosis. Non-functioning tumors are increasingly
recognised due to advanced imaging modalities such as endoscopic ultrasound
and thus became the most common GEP-NET in MEN1 patients. Contrary to
sporadic GEP-NETs, MEN1-associated cases are diagnosed 10 years earlier and
their penetrance is as high as 80-90%, reaching nearly that of the parathyroid
adenomas. Mutation analysis enables early tumor detection, thus the possibility to
prevent serious, even life-threatening morbidities associated with malignant GEP-
NET. Our aim was to identify phenotype features predictive for a positive MEN1
genetic test, and by comparing mutation-positive and mutation-negative patients
to evaulate the role of MEN1 mutations in phenotype modulation.
Design and methods
Of the 104 probands who fulfilled the criteria of MEN1 mutation analysis, 36
patients with GEP-NET were enrolled in this study. Mutation screeening of the
MEN1 gene by Sanger sequencing was performed at our national reference
laboratory. Clinical data were studied together with laboratory, imaging and
histological results. Multiple ligation probe amplification analysis of MEN1 gene
and Sanger sequencing of CDKN1B were carried out in clinically suspicious but
MEN1-negative cases.
Results
Of 36 GEP-NET patients mutation analysis demonstrated disease-causing
mutation in 19 patients. GEP-NET developed significantly earlier in mutation-
positive patients; more than half of them appeared under 30 years of age. The
prevalence of GEP-NET was also significantly higher at initial presentation in
mutation carriers compared to mutation negative patients. The presence of GEP-
NET under 30 years best predicted a positive MEN1 genetic test. Its prevalence
remained significantly higher among mutation carriers during the follow-up. In
addition, probands with high-impact mutations (frameshift, nonsense, large
deletions), predicted to affect menin function significantly, developed GEP-NETs
more frequently compared to low-impact (inframe and missense) mutation
carriers.
Conclusions
GEP-NETs appear significantly earlier and more frequently in MEN1-positive
patients and best predicted a positive genetic test. MEN1 patients with high-
impact mutations were more likely to develop GEP-NETs, revealing a possibly
important prognostic consequences regarding genetic counseling.
DOI: 10.1530/endoabs.56.P126
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Adrenocortical cancer – the effectiveness of mitotane therapy
depending on the time of therapy and the therapeutic dose
Kamil Ste˛pin´ski, Beata Jurecka-Lubieniecka, Barbara Michalik,
Sylwia Szpak-Ulczok, Przemysław Soczomski & Barbara Jarze˛b
Department of Nuclear Medicine and Endocrine Oncology. Maria
Skłodowska-Curie Institute – Oncology Center, Gliwice Branch, Gliwice,
Poland.
Introduction
Mitotane-o’p-DDD belongs to insecticides (DDT pesticide contamination), it is
the only drug registered by the FDA in treatment in adrenocortical carcinoma
(ACC). Treatment effect is controled by mitotane concentration in the blood.
Aim
The aim of the study is to evaluate the effectiveness of mitotane treatment in
patients with adrenocortical cancer.
Material and methods
We retrospectively reviewed data on ACC patients (nZ204) treated with
o,p 0DDD (nZ117) between 2002 and 2017. Finally, a total number of 55 patients
was included in the study. In these patients, we analysed a graph of mitotane
concentrations during the course of therapy. Therapeutic window of mitotan was
set according to the characteristics of the medicinal product (FDA) at 14-20 mg/l.
Patients were divided into two groups. For the study group, the inclusion criterion
was to maintain the concentration window of mitotane in the plasma least at 50%
of the treatment time. The study group included 17 people (31% of patients) The
comparative group group consisted of those who did not reach the therapeutic
window, 38 patients (69%). We observed patients from both groups in time one
year intervals after the inclusion of mitotane therapy. In the evaluation of the
effectiveness of the therapy, we based on the comparison of subsequent CT and
MR results according to RECIST criteria. Average duration of treatment was up
to 40 months in the first group of patients Average duration was of treatment was
up to 28 months in the second group of patients.
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